COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA. PRELIMINARY RESULTS

被引：0
|
作者：
Sabater, E. [1 ]
Rueda, A. [2 ]
Salar, A. [3 ]
Lopez-Guillermo, A. [4 ]
Oyagueez, I. [1 ]
Collar, J. M. [5 ]
机构：
[1] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[2] Hosp Costa del Sol, Dept Oncol, Marbella, Spain
[3] Hosp del Mar, Hematol Dept, Madrid, Spain
[4] Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain
[5] Mundipharma Pharmaceut, Dept Med, Madrid, Spain
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1270
引用
收藏
页码：487 / 488
页数：2
相关论文
共 50 条
  • [11] Healthcare Resource Utilization and Costs Associated with Obinutuzumab Plus Bendamustine Versus Rituximab Plus Bendamustine for First-Line Treatment of Follicular Lymphoma
    To, Tu My
    Ta, Jamie T.
    Seetasith, Arpamas
    Wang, Rongrong
    Lai, Dominic
    Shapouri, Sheila
    BLOOD, 2021, 138
  • [12] EVALUATING THE COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO CHEMOTHERAPY IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA PATIENTS IN THE UK
    Rafia, R.
    Papaioannou, D.
    Stevenson, M.
    Rathbone, J.
    Woods, H. B.
    VALUE IN HEALTH, 2011, 14 (07) : A445 - A445
  • [13] COST-EFFECTIVENESS OF DUVELISIB VERSUS THE BENDAMUSTINE PLUS RITUXIMAB REGIMEN FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA PATIENTS IN CHINA
    Chen, L.
    Tan, B.
    Gao, X.
    Zhou, K.
    Zhao, J.
    Xuan, J.
    VALUE IN HEALTH, 2023, 26 (12) : S181 - S182
  • [14] Cost-effectiveness analysis of first-line treatments for early-stage, low-grade follicular lymphoma.
    Yang, Joanna C.
    Elkin, Elena B.
    Parikh, Rahul
    Yahalom, Joachim
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [15] COST-EFFECTIVENESS ANALYSIS OF MAINTENANCE TREATMENT WITH RITUXIMAB IN PATIENTS WITH FOLLICULAR LYMPHOMA RESPONDING TO FIRST LINE INDUCTION THERAPY IN PORTUGAL
    Pereira, C.
    Rubio Terres, C.
    Rubio Rodriguez, D.
    VALUE IN HEALTH, 2014, 17 (07) : A530 - A531
  • [16] Clinical utility of interim CT scans in patients receiving bendamustine and rituximab for first line treatment of follicular lymphoma.
    Manji, Farheen
    Bhella, Sita
    Prica, Anca A.
    Kridel, Robert
    Kukreti, Vishal
    Kuruvilla, John
    Crump, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [17] BACOP/FND FIRST-LINE TREATMENT OF FOLLICULAR LYMPHOMA. MULTICENTRIC STUDY OF GISL PRELIMINARY RESULTS
    Luisi, D.
    Luminari, S.
    Amatetti, C.
    Merli, F.
    Brugiatelli, M.
    Baldini, L.
    Polimeno, G.
    Grinaldi, L.
    Fregoni, V.
    Giglio, M.
    Stellitano, C.
    Federico, M.
    Lombardo, M.
    ANNALS OF ONCOLOGY, 2004, 15 : 80 - 81
  • [18] BACOP/FR first-line treatment of follicular lymphoma. Multicentric study of GISL: Preliminary results
    Luisi, D.
    Luminari, S.
    Amatetti, C.
    Merli, F.
    Brugiatelli, M.
    Baldini, L.
    Polimeno, G.
    Grinaldi, L.
    Fregoni, V.
    Giglio, M.
    Stellitano, C.
    Marcheselli, L.
    Federico, M.
    Lombardo, M.
    ANNALS OF ONCOLOGY, 2005, 16 : 59 - 59
  • [19] First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis
    Pouyiourou, M.
    Meyer, A.
    Stroux, A.
    Viardot, A.
    La Rosee, P.
    Maschmeyer, G.
    Kaempfe, D.
    Kahl, C.
    Vucinic, V.
    Monecke, A.
    Hirt, C.
    Weber, T.
    Meissner, J.
    Witzens-Harig, M.
    Boettcher, S.
    Schmalenberg, H.
    Marks, R.
    Prange-Krex, G.
    Kroschinsky, F.
    Hauf, E.
    Keller, U.
    Koch, K.
    Klapper, W.
    Herold, M.
    Scholz, Christian W.
    ANNALS OF HEMATOLOGY, 2020, 99 (12) : 2821 - 2829
  • [20] First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis
    M. Pouyiourou
    A. Meyer
    A. Stroux
    A. Viardot
    P. La Rosée
    G. Maschmeyer
    D. Kämpfe
    C. Kahl
    V. Vucinic
    A. Monecke
    C. Hirt
    T. Weber
    J. Meissner
    M. Witzens-Harig
    S. Böttcher
    H. Schmalenberg
    R. Marks
    G. Prange-Krex
    F. Kroschinsky
    E. Hauf
    U. Keller
    K. Koch
    W. Klapper
    M. Herold
    Christian W. Scholz
    Annals of Hematology, 2020, 99 : 2821 - 2829
12345